Klotho Protein and Aging: What the 1997 Japanese Discovery Actually Shows

Jun 12, 2026

Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published molecular biology and aging cohort research. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before making changes to your diet, supplement regimen, or any health-related decision.

In 1997, a team at the University of Tokyo led by Makoto Kuro-o published a paper in Nature describing a mouse with an unusual aging phenotype. The animal appeared normal at birth, then within weeks began accumulating features that in humans take decades to develop: calcified arteries, bone loss, skin atrophy, pulmonary damage, and a severely shortened lifespan. The cause was a single disrupted gene — one Kuro-o’s team named klotho, after Clotho, the Greek Fate who spins the thread of life.

That naming choice reflected how the researchers understood what they had found: not a single-organ disease gene, but a potential regulator of the rate of aging itself. The decades of research since have developed that hypothesis into one of the more scientifically grounded stories in molecular aging biology — and a clear example of how Japanese basic science has reshaped how the field thinks about aging.

TL;DR

Makoto Kuro-o and colleagues at the University of Tokyo identified the KL gene in 1997 after characterizing mice with a disrupted gene that produced an accelerated aging syndrome spanning multiple organ systems
Klotho protein exists in two functional forms: a membrane-bound co-receptor for FGF23 (fibroblast growth factor 23) and a shed soluble form that circulates in blood
Klotho overexpression in mice extends lifespan; deficiency produces premature aging — bidirectional genetic evidence linking a single gene to aging rate in a mammal
Serum Klotho in humans declines with age in cross-sectional cohort data; lower serum Klotho is associated with markers of biological aging in several population studies including Japanese cohort analyses
Primary expression is in the kidney; Klotho is a sensitive early indicator of kidney function decline and the Klotho-FGF23 axis connects kidney health to cardiovascular and skeletal outcomes
Calibration: the mouse model evidence is the most robust layer of this research; human observational cohort data exists but is cross-sectional; human RCTs on Klotho are not yet available — mouse-to-human translation remains ongoing

The 1997 discovery: what Kuro-o’s team actually found

The klotho gene was not identified through a hypothesis-driven search for an aging gene. Kuro-o’s group was using insertional mutagenesis — a technique that disrupts random genomic locations by inserting foreign DNA — and observed that one disrupted mouse line developed a premature aging syndrome. Characterizing the disrupted gene led to the identification of a previously unknown sequence, now designated KL in official nomenclature and named klotho by the discoverers.

The phenotype in klotho-deficient mice was notable in its breadth. Animals appeared normal at birth but by four to five weeks of age showed growth retardation and began accumulating features: calcification in arteries, trabecular bone loss, skin atrophy with reduced subcutaneous fat, alveolar destruction in the lungs, and atrophy of reproductive organs. Lifespan was truncated to approximately 60 days, compared to the 700–900 days typical for the mouse strain. The researchers described this as a premature aging syndrome because it combined — in a compressed timeframe — changes that in normal aging accumulate slowly across years.

The complementary result arrived in 2005, when Kurosu and colleagues published in Science a study of mice engineered to overexpress Klotho. These animals lived approximately 20–30% longer than controls, with extension observed in both sexes. That bidirectional evidence — deficiency accelerates aging-like deterioration, overexpression extends lifespan — makes Klotho one of a small number of single genes in mammals where the connection to aging rate has been demonstrated in both directions. The SIRT6 data, covering a related genetic manipulation, sits in similar conceptual territory; the SIRT6 and sirtuin research cluster is covered in the sirtuins and NAD+ article.

What the Klotho protein does

The protein encoded by KL is a single-pass transmembrane protein expressed most highly in the kidney’s distal convoluted tubule, and at lower levels in brain (choroid plexus), parathyroid gland, and skeletal muscle. It exists in two major functional forms that have different reach and different actions.

The membrane-bound form functions as a co-receptor for FGF23, a hormone secreted by osteocytes in bone that signals the kidney to reduce phosphate reabsorption and suppress the activation of vitamin D. Membrane-bound Klotho forms a complex with the FGF receptor (FGFR1c) in the renal tubule that is required for FGF23 to signal effectively. Without Klotho, FGF23 cannot bind properly — and the kidney cannot respond to the “reduce phosphate reabsorption” signal. In klotho-deficient mice, this produces hyperphosphatemia (excess circulating phosphate) despite elevated FGF23, because the signaling machinery that would respond to FGF23 is absent. Phosphate accumulation then drives much of the vascular calcification and organ damage observed in the knockout phenotype.

The soluble form — produced when membrane proteases cleave the extracellular domain of membrane Klotho and release it into the bloodstream — circulates in blood, urine, and cerebrospinal fluid. This shed form retains some FGF23 co-receptor activity and separately functions as a direct inhibitor of Wnt and TGF-β signaling pathways, both of which are associated with cellular senescence and tissue fibrosis when chronically elevated. The Wnt inhibitory activity of soluble Klotho has attracted interest in stem cell and tissue regeneration research, though most evidence on this mechanism comes from cell culture and animal models.

The distinction between the two forms matters for translational research: the membrane form’s FGF23 co-receptor function is local to tissues where Klotho is expressed; the soluble form circulates and could in principle reach distant organs. This is why serum Klotho measurements — which detect the soluble form — are used as a proxy for systemic Klotho activity in human cohort research.

Serum Klotho and human aging: the cohort picture

Several population studies have measured soluble Klotho in human blood and examined its relationship to aging-related outcomes. The findings are consistent in direction but share the structural limitations of observational cross-sectional data.

Serum Klotho is associated with declining levels across the adult lifespan in cross-sectional samples. Studies in Japanese and American populations find that individuals in their 60s and 70s carry lower circulating Klotho concentrations than those in their 40s and 50s, when measured with established immunoassay methods. Whether this decline reflects reduced kidney production (the primary cellular source of circulating Klotho), altered cleavage dynamics, or increased consumption by target tissues is not fully established.

The InCHIANTI cohort — a longitudinal aging study enrolling older community-dwelling adults in Tuscany — produced one of the more-cited analyses of serum Klotho and physical function. Semba and colleagues found that lower serum Klotho was associated with poorer muscle strength and walking speed in older participants, independent of kidney function markers as covariates. A follow-up analysis found lower baseline Klotho associated with faster progression of functional decline over follow-up. These are associative findings; whether lower Klotho contributes to functional decline, is a consequence of the same underlying biological processes, or reflects a correlated third variable cannot be separated from observational data alone.

Japanese geriatric cohort analyses — including work from groups at Tohoku University examining community-dwelling older Japanese adults — have found similar cross-sectional associations between serum Klotho and markers of biological aging, including arterial stiffness indices, bone density measurements, and physical performance composites. The direction of association is consistent with the InCHIANTI and American population data, suggesting the serum Klotho decline-aging relationship is not specific to one ethnic group. Whether the rate of decline differs across populations has not been established with sufficient sample sizes.

Multi-organ effects: kidney, bone, cardiovascular, brain

The organ-specific evidence around Klotho organizes into four areas, with varying strength of evidence across them.

Kidney: The kidney is both the primary producer and a primary target of Klotho signaling. In chronic kidney disease (CKD), renal Klotho expression falls early and substantially — often before standard kidney function markers show significant impairment in serum creatinine or eGFR. This early decline reduces the kidney’s capacity to respond to FGF23, which rises in CKD as the kidneys attempt to drive phosphate excretion. The resulting elevated FGF23 / low Klotho state is associated with accelerated cardiovascular risk in CKD patients — through direct cardiac effects of elevated FGF23 and secondary effects of phosphate retention on vascular calcification. The CKD-mineral-bone disorder literature represents the closest current approach to clinical application of Klotho biology, though the practical intervention here remains phosphate management and CKD care rather than Klotho supplementation.

Bone and mineral metabolism: Because Klotho co-regulates FGF23 and vitamin D activation, deficiency disrupts calcium and phosphate homeostasis. The osteoporosis-like bone changes in klotho-deficient mice appear driven primarily by abnormal mineral metabolism, with phosphate excess as the dominant mechanism. Human observational data shows associations between lower serum Klotho and lower bone mineral density in older adults; the effect sizes are modest and do not establish clinical utility for serum Klotho as a bone risk predictor.

Cardiovascular: Vascular calcification, endothelial dysfunction, and impaired nitric oxide-dependent vasodilation are features of klotho-deficient mice and are associated with lower Klotho in vascular biology research. In observational human data, lower serum Klotho is associated with higher arterial stiffness scores, independent of traditional cardiovascular risk factors, in several cohort analyses. The direction of association is consistent; whether this represents a causal relationship requires interventional data not yet available.

Cognitive function: A genetics finding added a distinct angle to the Klotho story. A specific variant haplotype called KLOTHO-VS has been associated with better cognitive performance in genetic studies, including work by Dubal and colleagues published in 2014. Carriers of one copy of the VS haplotype showed higher performance on multiple cognitive tests across several independent cohorts. Proposed mechanisms include effects on brain-derived neurotrophic factor (BDNF) signaling and synaptic maintenance, though the molecular pathway from KLOTHO genotype to cognitive outcomes in humans involves multiple steps not yet directly measured. Cross-sectional observational data in older Japanese adults also finds associations between serum Klotho and cognitive test scores, consistent with the genetics picture.

What the mouse model cannot yet establish

The Klotho research program has produced unusually coherent animal model evidence — the bidirectional aging phenotype data remains among the most cited in molecular gerontology. But several important gaps limit direct application to human health decisions.

No human RCT on Klotho supplementation exists. Soluble Klotho is a protein and cannot be administered orally. Preclinical work has examined recombinant soluble Klotho infusion in animal models of aging and kidney disease with positive results in some organ-specific endpoints, but human clinical trials of recombinant Klotho are in early development stages. None has reported longevity or functional aging outcomes.

Serum Klotho measurement lacks clinical-grade validation. Despite two decades of research, there is no validated clinical reference range for serum Klotho that guides intervention. Assay variability across measurement platforms is a documented issue in the field, complicating comparisons between studies and making population reference ranges difficult to establish.

The knockout phenotype may reflect phosphate toxicity more than generalized accelerated aging. Several researchers have argued that what the klotho-knockout mouse demonstrates is primarily a severe mineral metabolism disorder — hyperphosphatemia from impaired FGF23 signaling — rather than accelerated aging per se. When dietary phosphate is restricted in klotho-deficient animals, many of the aging-like features are substantially reduced. This does not eliminate Klotho’s relevance to aging, but it constrains interpretation: the dramatic phenotype may not map directly onto the more modest Klotho variation seen across healthy human aging.

Observational associations require causal confirmation. The human cohort data consistently shows correlations between lower serum Klotho and aging-related outcomes. But lower Klotho in older, less healthy populations may be a downstream consequence of declining kidney function and advancing biological age rather than a contributing driver. Separating these directions requires the kind of interventional data that does not yet exist.

Practical framing

Klotho occupies an interesting position in the longevity research landscape: the underlying molecular biology is substantive and well-characterized, but the translational distance to any individual health action remains large. What the current evidence does and does not support:

Kidney health: the Klotho-FGF23 axis is a legitimate consideration for anyone managing chronic kidney disease. Dietary phosphate management — a standard CKD strategy — addresses the same phosphate metabolism pathway that Klotho deficiency dysregulates. This is the area where Klotho biology has the clearest clinical relevance, operating through established kidney care rather than Klotho-specific supplementation.

Aerobic exercise: several human studies, including work from Japanese research groups, have found that regular aerobic exercise is associated with higher serum Klotho levels in cross-sectional and pre-post study designs. Effect sizes vary across studies, and the mechanism — possibly through improved renal perfusion, reduced inflammatory signaling, or both — is not fully characterized. It represents one of the more consistent actionable correlates in the human Klotho observational literature.

For research reading: the primary literature on Klotho is accessible and scientifically substantial. The 1997 Kuro-o Nature paper and the 2005 Kurosu Science overexpression paper are foundational. For a broader picture of how Klotho connects to the longevity biology cluster — sirtuins, epigenetic clocks, centenarian genetics, autophagy — several research-grounded books on aging biology are available on Amazon. For those interested specifically in how Japanese science has contributed to this research landscape, books covering Japanese longevity science and anti-aging research are also available on Amazon.

The Klotho story connects directly to the other molecular aging programs in the Choju Lab research cluster. Klotho overexpression appears to attenuate insulin/IGF-1 signaling — the same pathway that FOXO3 activation under caloric restriction engages through SIRT1 deacetylation, documented in the sirtuins and NAD+ article. The centenarian genetics context — including how FOXO3 variants from Okinawan cohort data sit within the IGF-1 signaling axis — is covered in the centenarian genome article. And cellular senescence — which Klotho deficiency accelerates in mouse tissue — is connected to autophagy flux impairment, the molecular maintenance process whose core machinery Yoshinori Ohsumi characterized through work covered in the Ohsumi Nobel and autophagy article. Each of these connections is biologically plausible and consistent with current evidence; none has been confirmed at clinical-outcome level in humans, which is the appropriate epistemic floor for this stage of translational research.